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Abstract
Inflammation and autophagy have emerged as prominent issues in the context of proteoglycan 
signaling. In particular, two small, leucine-rich proteoglycans, biglycan and decorin, play pivotal 
roles in the regulation of these vital cellular pathways and, as such, are intrinsically involved in 
cancer initiation and progression. In this minireview we will address novel functions of biglycan 
and decorin in inflammation and autophagy, and analyze new emerging signaling events triggered 
by these proteoglycans, which directly or indirectly modulate these processes. We will critically 
discuss the dual role of proteoglycan-driven inflammation and autophagy in tumor biology, and 
delineate the potential mechanisms through which soluble ECM constituents affect the 
microenvironment associated with inflammatory and neoplastic diseases.
Graphical Abstract
We critically asses the role of two small, leucine-rich proteoglycans, biglycan and decorin, in 
inflammation and autophagy. The signaling axes of these two proteoglycans are operative during 
various stages of cancer initiation and progression. Moreover, we discuss the dual role of 
proteoglycan-driven inflammation and autophagy in tumor biology, and offer unique roles for 
these molecules as potential therapeutic agents.
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Introduction
For decades, the two closely related small, leucine-rich proteoglycans (SLRPs), biglycan and 
decorin, have been considered as rather structural elements of the extracellular matrix 
(ECM). For example, biglycan has long been regarded as an important factor for bone 
mineralization and decorin originally gained recognition for its role in the regulation of 
collagen fibrillogenesis [1]. However, this paradigm shifted when biglycan and decorin were 
identified as functional signaling molecules, particularly in the context of inflammation and 
autophagy regulation. As these processes play a crucial role both in the initiation and 
progression of tumorigenesis, and as these proteoglycans distinguish themselves further as 
dynamic players in cell signaling, it has become apparent that biglycan and decorin, and 
their downstream signaling effectors, might represent druggable therapeutic targets for the 
treatment of malignant disease. The role of syndecan and heparanase, two key players in 
cancer progression, is also covered in this thematic minireview series [2,3].
In this review, we provide an inclusive and critical assessment of the roles of biglycan and 
decorin in autophagy as well as in inflammatory signaling pathways, with a strong emphasis 
on their functions in the setting of cancer. We will further evaluate the intricate connection 
between these endogenous matrix constituents and both normal and pathological cellular 
activity to provide insight into future options for the treatment of cancer and other diseases 
where inflammation is predominant.
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Matrix regulation of endothelial cell autophagy and tumor cell mitophagy
Neovascularization is a long-standing hallmark in the context of cancer progression as the 
growth of new blood vessels allows the tumor proper to acquire necessary nutrients to 
enlarge and metastasize. As such, the advent of anti-angiogenic compounds has opened a 
new era of cancer treatment and the development of next-generation angiogenesis inhibitors 
remains a popular basis for chemotherapeutic drug design. Though a variety of 
pharmacologic agents have been engineered to target this process, an important discovery 
revealed that the ECM harbors an endogenous angiostatic factor in the class I small, leucine-
rich proteoglycan, decorin [4]. Initial studies have demonstrated the ability of decorin to 
regulate collagen fibrillogenesis, thereby establishing a function for decorin in the 
preservation of the structural integrity of ECM [5–9]. Subsequent work has revealed that 
decorin plays a much more active role by regulating key cellular processes through its 
aptitude for binding to different receptor tyrosine kinases (RTKs) and modifying 
downstream signaling pathways [10–20]. In tumor cells, decorin acts primarily through the 
hepatocyte growth factor (HGF/Met) and epidermal growth factor receptor (EGFR) 
signaling axes to decrease the expression of the pro-angiogenic factors, vascular endothelial 
growth factor A (VEGFA) and hypoxia-inducible factor 1-α (HIF-1α), while 
simultaneously increasing the expression of thrombospondin-1 [11,21], a powerful anti-
angiogenic protein [22], and tissue inhibitor of metalloproteinases-3 (TIMP3) [11,21], a key 
regulator of ECM turnover [11,21] (Fig. 1). The cumulative effect of these changes of the 
tumor secretome creates an anti-angiogenic and, subsequently less metastatic, tumor 
microenvironment.
Though decorin can alter the cellular milieu by controlling the secretion of angiogenic 
factors from tumor cells themselves, more recent work has uncovered a novel mechanism 
where decorin attenuates tumor progression by directly targeting the tumor 
microenvironment rather than acting solely on the tumor proper. A unique screen of 
orthologous tumor xenografts capable of differentiating between human and mouse gene 
expression revealed an increase in the tumor suppressor gene, paternally expressed gene 3 
(Peg3), in decorin-treated animals compared to vehicle-treated controls [23]. Interestingly, 
this decorin-evoked gene induction occurs only in the tumor stroma and not in the tumor 
itself [23]. Given this information, a more detailed analysis of Peg3 expression in tumor-
supporting cells upon decorin treatment revealed that Peg3 plays a role in mediating 
endothelial cell autophagy, the accumulation of cytoplasmic contents in double-membrane 
structures, which are eventually degraded via lysosomal machinery [24,25]. Mechanistically, 
decorin acts as a partial agonist for vascular endothelial growth factor receptor 2 (VEGFR2), 
the main receptor responsible for facilitating the angiogenic response in endothelial cells, 
resulting in a signaling cascade culminating in Peg3-dependent canonical autophagy 
involving the standard autophagic intermediates, Beclin 1 and microtubule-associated light 
chain protein 3 (LC3) [13,17] (Fig. 1). Decorin also competes with VEGFA, the canonical 
ligand of VEGFR2, to hinder angiogenesis [26]. As VEGFR2 is specifically expressed on 
endothelial cells, it is plausible that the anti-angiogenic property of decorin is linked to its 
induction of autophagy exclusively in the tumor vasculature. These findings are the first to 
link a soluble extracellular proteoglycan to the induction of the catabolic process of 
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autophagy and expose a novel function for matrix molecules to regulate the lysosomal 
degradation pathway.
Regarding the aforementioned decorin-mediated alteration of thrombospondin-1 secretion 
by tumor cells, it appears that thrombospondin-1 is surfacing as an important autophagic 
signaling molecule. For example, thrombospondin-1 inhibits RAS-positive tumor cell 
growth via autophagic induction [27]. On the contrary, studies blocking the function of 
CD47, the main thrombospondin-1 receptor, show a paradoxical increase in autophagic 
activity [28]. Thus, the ability of thrombospondin-1 to modulate autophagy appears to be 
quite complex, but may be important for putting together more pieces of the puzzle to 
understand better the ability of decorin to inhibit neovascularization.
Also of importance is the recent discovery that decorin is an autophagy-inducible 
proteoglycan [12,16] where nutrient deprivation and chemical inhibition of mammalian 
target of rapamycin (mTOR) signaling augment its expression both in vitro in fibroblasts as 
well as in vivo in cardiac tissue. In addition, Dcn−/− mice exhibit diminished cardiac 
autophagy vis-à-vis wild-type mice following a fasting challenge [12], validating the 
importance of decorin as a pivotal control center for the regulation of this catabolic process 
[16]. As pro-autophagic stimuli increase decorin expression, it is possible that the ability to 
modulate decorin levels in the tumor stroma may be a novel method for targeting 
neovascularization in the setting of cancer. Furthermore, in order to connect the processes of 
tumor progression and autophagy, a worthy hypothesis may be that, in the absence of 
decorin, lower levels of autophagy promote a pro-tumorigenic microenvironment.
In contrast, biglycan, another class I SLRP that shares the most structural homology with 
decorin [29,30], possesses pro-angiogenic properties through its ability to bind VEGFA and 
activate VEGFR2 signaling [31]. Additionally, when overexpressed in colon cancer cells, 
biglycan upregulates VEGFA leading to increased angiogenesis and tumor growth through 
activation of the extracellular signal-regulated kinase (ERK) pathway [32]. Therefore, the 
capacity to modulate angiogenesis appears to be specific to each respective proteoglycan, 
even within closely related members of the same family. Whether biglycan-mediated 
angiogenesis is related to autophagy remains to be seen. Interestingly, biglycan inhibits the 
angiostatic effects of endostatin [30]. As endostatin is a potent autophagic inducer in 
endothelial cells through the modulation of α5β1 integrin signaling culminating in increased 
Beclin 1 expression [30], it is possible that biglycan may inhibit autophagy by diminishing 
endostatin activity.
Like biglycan, perlecan, a large, basement membrane proteoglycan, exhibits pro-angiogenic 
properties [33–45]. Specifically, through its heparan sulfate side chains, the N-terminal 
domain I of perlecan sequesters and presents VEGFA and fibroblast growth factors (FGFs) 
to their respective receptors resulting in enhanced angiogenesis [46–51]. Importantly, mice 
that have been genetically designed without the heparan sulfate attachment site display 
diminished angiogenesis and compromised wound healing, presumably due to impairment in 
the juxtaposition of growth factors with their signaling receptors [52,53]. Along with its pro-
angiogenic properties, perlecan also appears to be anti-autophagic as a recent notable 
discovery illustrates that conditional Heparan sulfate proteoglycan 2−/− (Hspg2−/−) mice 
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display enhanced autophagy in skeletal muscle [54] where they exhibit less mTOR activity 
than wild-type cohorts.
We note that perlecan is a multi-modular proteoglycan, where different domains serve 
different functions [55]. For example, while its N-terminal domain is pro-angiogenic, its C-
terminal fragment, endorepellin, embraces properties very similar to those of decorin, where 
it is capable of restricting endothelial cell migration, capillary morphogenesis, and 
angiogenesis [35]. Indeed, previous studies demonstrate that endorepellin exclusively targets 
the tumor vasculature, resulting in decreased tumor growth [56]. In addition, endorepellin is 
able to initiate autophagy in endothelial cells utilizing a mechanism comparable to that of 
decorin, as both work through the Peg3-signaling axis to induce the pro-autophagic 
intermediates Beclin 1 and LC3 [57]. As both endorepellin and decorin exhibit the capability 
to induce autophagy as well as inhibit tumorigenesis through their actions in the tumor 
microenvironment, it is again likely that one mechanism by which this occurs is via 
suppression of angiogenesis through autophagic degradation of the vasculature. In fact, 
recent work suggests that the angiostatic mechanism of endorepellin is directly linked to 
autophagic induction [58]. Specifically, endorepellin inhibits vessel sprouting in ex vivo 
aortic ring assays, which can be blocked by inhibiting autophagy via the adenosine 
monophosphate kinase (AMPK) inhibitor, compound C [58]. Therefore, as decorin follows 
this same mechanistic paradigm, it is likely that it too reduces tumor neovascularization via 
an autophagic mechanism. Interestingly, endorepellin interacts with endostatin [35], the 
aforementioned potent pro-autophagic matrix protein. As this interaction diminishes 
endostatin’s ability to reduce angiogenesis in endothelial cells, it may also prevent 
autophagic induction by either protein via a competitive binding mechanism.
Taken together, it appears that a distinct network is arising in the ECM that is important for 
the regulation of normal cell homeostasis as well as to counteract dysregulation of 
homeostasis in the tumor microenvironment. In vivo, it seems that there exist intricate 
feedback loops to allow for the induction and suppression of both autophagy and 
angiogenesis in response to environmental cues. Preliminary evidence for this stems from 
the observation that anti-angiogenic proteoglycans, like decorin [4], seem to be pro-
autophagic and vice versa. As an aberration of either process can be detrimental to normal 
physiology, these pathways may become deregulated following some sort of insult or 
environmental stressor, leading to the onset of cancer. Continued deregulation may 
contribute to the progression of cancer and eventually to metastasis. As we continue to 
examine the signaling capabilities of these proteoglycans, we will gain a better perspective 
about the changes in the tumor microenvironment that lead to metastasis and how they are 
related to proteoglycan function or dysfunction. Furthermore, this knowledge will provide 
new management options for cancer where mimetics of endogenously occurring matrix 
components can be utilized for a safer, more efficacious treatment regimen than existing 
options.
Curtailing cancer progression: Targeting the tumor proper
Though we have focused mainly on detailing the actions of decorin and related 
proteoglycans in the tumor stroma, we must acknowledge that decorin, which is biologically 
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active as a monomer [59], also engages directly with the tumor proper via its interaction 
with a variety of RTKs abundant on the surface of different types of cancer cells [60–62]. 
One of the best-known decorin/RTK interactions is that between decorin and the EGFR 
resulting in p21-mediated cell cycle arrest, apoptosis, and diminished angiogenesis [63–65] 
(Fig. 1). Furthermore, decorin allows for EGFR to be degraded via caveolin-mediated 
endocytosis [66]. In addition, decorin antagonizes ErbB2/4 and platelet-derived growth 
factor (PDGF) signaling, both resulting in decreased tumor growth [67–69].
As described above, decorin interacts with the HGF/Met receptor to reduce angiogenesis by 
modifying the tumor secretome [70] (Fig. 1). In the tumor parenchyma, this same interaction 
results in an attenuation of β-catenin and Myc signaling, thereby directly inhibiting tumor 
growth [71] (Fig. 1). Notably, the decorin/Met interaction in triple-negative breast carcinoma 
cells evokes tumor cell mitophagy via the tumor suppressor, mitostatin [72] (Fig. 1). This 
decorin-evoked mitophagy likely comes as a consequence of mitochondrial depolarization 
and is the first documentation that decorin can regulate catabolism in cancer cells. Thus, it is 
likely that some of decorin’s anti-tumorigenic activity comes through its interference with 
proper oxidative phosphorylation resulting in an energy imbalance in the setting of cancer. 
Furthermore, loss of mitostatin results in the inability of decorin to suppress VEGFA [72], 
coupling the ability of decorin to act simultaneously in the tumor microenvironment and the 
tumor proper.
Canonical autophagy in tumor cells in response to decorin stimulation has been recently 
reported in glioma cells, where decorin-mediated autophagic induction contributes to a 
reduction in cellular migration [73]. Though this is the first report of decorin-induced 
autophagy directly in cancer cells, it is likely that tumor cells that possess the proper 
receptors and subsequent signaling machinery also undergo autophagy in response to 
decorin treatment. For example, recent studies posit that inhibition of EGFR signaling 
results in autophagic induction [74]. As decorin is a potent ligand of EGFR, it is probable 
that tumor cells over-expressing this receptor, such as A431 squamous carcinoma cells or 
A549 lung carcinoma cells, respond with canonical autophagy instead of, or in concert with, 
mitophagy when challenged with decorin. Nevertheless, as our lab has demonstrated the 
necessity of Peg3 for decorin-mediated autophagy in endothelial cells, it would be 
unsurprising if decorin induces autophagy only in few tumor types as many cancers possess 
little to no endogenous Peg3 [75,76].
Again, despite being in the same family, biglycan takes on different functions in the context 
of tumor signaling. In fact, several tumor types, including colon and pancreatic cancer, 
express biglycan at higher levels than normal tissue substantiating the idea that biglycan is 
pro-tumorigenic as well as pro-angiogenic [77–79]. For instance, upregulation of biglycan in 
gastric cancer mechanistically promotes invasion and migration of these cells via 
phosphorylation and consequent activation of the focal adhesion kinase (FAK) signaling 
pathway [80]. In colon cancer cells, depletion of biglycan results in decreased proliferation 
and p21-mediated cell cycle arrest [32]. In addition, biglycan is capable of inhibiting 
apoptosis in these colon cancer cells by regulating p38 MAPK signaling [32]. Moreover, 
though its ability to augment Wnt/β-catenin signaling has only been explored in bone, some 
of the pro-tumorigenic effects of biglycan may also be attributed to its ability to amplify 
Schaefer et al. Page 6
FEBS J. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wnt/β-catenin signaling as well as its ability to interact with LDL-receptor related protein 6 
(LRP6) [81]. Interestingly, autophagy attenuates Wnt-signaling, suggesting a potential link 
between biglycan and this catabolic process in cancer [82]. Also, though direct alterations of 
signaling pathways via biglycan are largely responsible for increased tumorigenesis, a 
secondary mechanism may be the ability of biglycan to modify the biophysical properties of 
the matrix itself. For example, as biglycan modifies FAK-signaling, it is likely that some of 
the increased invasiveness and tumor progression resulting from biglycan overexpression 
may come as a result of increased matrix stiffness, thereby facilitating the migration of 
cancer cells to increase metastasis.
Though the function of autophagy in cancer is controversial, it is emerging as an important 
therapeutic target. Whether it should be enhanced or inhibited appears to be context-
dependent as in some cases autophagy is beneficial for reducing tumor growth and in others 
it seems necessary for cancer cell survival. Regardless, as both decorin and biglycan are 
major players in the inhibition and progression of tumorigenesis, parsing out the mechanism 
behind modulation of the autophagic pathway by them and other matrix constituents is 
critical for comprehending how to best fine-tune novel treatment strategies. Though the role 
of decorin in autophagy as it pertains to cancer is much more well-established than that of 
biglycan, it is very probable that biglycan will develop into a remarkable player in this 
signaling pathway in the future. Thus, we must focus our efforts on discovering more of the 
intricacies of these signaling regimes to hone our understanding of matrix regulation of 
tumor initiation and metastasis.
Complexity of biglycan signaling: Pro-inflammatory and danger signals
Besides its function as a structural molecule, the small leucine-rich proteoglycan biglycan 
can be either proteolytically released from the ECM upon tissue stress and injury or de novo 
synthesized by activated macrophages and resident cells [83]. In its soluble form, biglycan 
acts as a signaling molecule and endogenous ligand of the Toll-like receptors (TLR)-2 and -4 
on the surface of macrophages. This biological interaction autonomously triggers sterile 
inflammation and potentiates pathogen-mediated inflammation via a second TLR that is not 
involved in pathogen sensing [83–85]. Mechanistically, by engaging TLR2 and TLR4, 
biglycan rapidly activates p38, ERK, and NF-κB signaling pathways. This leads to the 
synthesis and secretion of pro-inflammatory cytokines and chemokines, such as interleukin 
(IL)-1β, tumor necrosis factor (TNF)-α, chemokine (C–C motif) ligand (CCL)2, chemokine 
(C-X-C motif) ligand (CXCL)1, CXCL-2, CXCL13, and CCL5 [83,84,86,87] (Fig. 2). This 
process initiates modulation of the immune environment and facilitates the recruitment of 
leukocytes to the site of inflammation.
The use of a transient transgenic mouse model in which biglycan is overexpressed in the 
liver under the albumin promoter and then released into the circulation has been instrumental 
for the deeper understanding of biglycan signaling in vivo [87]. This model has elucidated 
that soluble biglycan uses TLR2/4 signaling pathways, involving the adaptor molecule 
myeloid differentiation primary response 88 (MyD88), for the recruitment of neutrophils and 
macrophages while it regulates the infiltration of T cells exclusively through TLR4 and the 
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adaptor molecule TIR-domain-containing adapter-inducing interferon-β (TRIF) [87,88] 
(Fig. 2).
Moreover, biglycan organizes a multi-receptor crosstalk between TLR2/4 and the purinergic 
receptor, P2X7 [85]. By clustering TLR2/4 and P2X7, biglycan triggers the activation of 
caspase-1 through the NOD-like receptor protein 3 (NLRP3) inflammasome with 
subsequent release of mature IL-1β and IL-18 in a reactive oxygen species (ROS)- and heat 
shock protein (HSP)-90-dependent manner [85]. As a consequence, biglycan-deficient mice 
show improved survival in LPS-induced sepsis and less severe inflammation in both models 
of sterile inflammatory renal injury and LPS-induced sepsis, as monitored by decreased 
levels of active caspase-1 and therefore of mature IL-1β [83,85,89] (Fig. 2).
Thus, under pathological conditions soluble biglycan in its intact form, containing protein 
core and glycosaminoglycan (GAG) chain(s), and some biglycan fragments act as potent 
danger signals that mimic response to Gram-positive (via TLR2) and negative (via TLR4) 
pathogens [90]. While it is well established that the interaction of biglycan with TLR2 and 
the TLR4/MD2 complex occurs via protein core [83,84] the exact binding motifs are still 
under investigation. Interestingly, for the induction of TLR-dependent signaling the protein 
core of biglycan and at least one GAG side chain are required. Neither biglycan protein core 
nor GAG chains alone are capable of inducing TLR-dependent signaling and a 
proinflammatory response [83]. Therefore, it is conceivable that GAG chains of biglycan 
might be involved in the interaction with co-receptors and adaptor molecules of TLR2 and 
TLR4.
Proteolytic release of biglycan ensures a rapid inflammatory response to tissue stress or 
injury without the need for the de novo synthesis of biglycan. Several proteolytic enzymes 
such as bone morphogenetic protein-1 (BMP-1) [91], various matrix metalloproteinases 
(MMPs) [92] and a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS) and serine protease Granzyme B (GrB) have been shown to cleave biglycan. For 
details on biglycan degrading enzymes and cleavage of biglycan please refer to the recent 
review [93]. The fragments of biglycan acting as danger signals and proteinases involved in 
their generation are not identified yet. As biglycan protein core together with GAG side 
chain(s) trigger a proinflammatory response, it is tempting to speculate that not all of the 
generated biglycan fragments will be capable of binding to TLR2 and TLR4. Therefore, a 
proper inflammatory signal is secured by a very fast, de novo synthesis of biglycan in 
stimulated macrophages followed by additional synthesis in resident cells.
Biglycan tightly controls the severity of the inflammatory response
A novel mechanism has emerged wherein biglycan fine-tunes IL-1β production and restores 
immune homeostasis [89]. By using TLR2/4, biglycan triggers ROS generation in 
macrophages through NADPH oxidases (NOX) 1 and 4, thereby enhancing the expression 
and secretion of IL-1β. To impede this self-induced pro-inflammatory response, biglycan 
also triggers the synthesis and activation of NOX2 through selective TLR4 signaling 
pathways. While biglycan-mediated TLR4/TRIF signaling leads to the induction of Nox2 
mRNA expression, induction of TLR4/MyD88 signaling is required for activation of NOX2. 
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Activated NOX2 inhibits biglycan-mediated IL-1β synthesis [89]. It is tempting to speculate 
that these mechanisms of self-limiting inflammation are involved under physiological 
conditions to fine-tune IL-1β levels and could be therapeutically harnessed to treat 
inflammatory diseases.
However, there is strong evidence for beneficial effects of biglycan deficiency and pro-
inflammatory effects of biglycan overexpression in various inflammatory diseases [93,94]. 
In fact, under pathological conditions biglycan stimulates the expression of HSP70 by 
selective utilization of TLR2. HSP70 binds to NOX2 thereby inducing its proteasomal 
degradation. This interaction consequently impairs the inhibitory function of NOX2 on 
IL-1β expression, promoting pro-inflammatory effects of biglycan (Fig. 2). Accordingly, in a 
mouse model of sterile renal inflammation, the lack of biglycan in Nox2-deficient mice is 
protective of hyperinflammation as well as massive macrophage infiltration, leading to less 
severe kidney damage [89].
Thus, these data describe how danger signals control the severity of the inflammatory 
response, by utilizing multi-receptor signaling, selective induction of TLR2 and TLR4 
signaling pathways, adaptor molecules and downstream events such as ROS production. The 
discovery of the dual role of biglycan in inflammation will open new prospects for 
therapeutic intervention. It is likely that selective inhibition of biglycan-TLR2- or biglycan-
TLR4 signaling could be a new therapeutic approach in inflammatory diseases. 
Alternatively, the stabilization of biglycan-mediated NOX2 expression or activation might 
represent a novel pharmacological avenue to overcome inflammation without interfering 
with physiological TLR signaling.
Biglycan stabilizes HIF-2α and evokes erythropoiesis
Recently, a novel function of biglycan has been discovered in a transgenic mouse model in 
which biglycan was constitutively overexpressed. Surprisingly, chronic increase in 
circulating biglycan leads to elevated hemoglobin concentrations, hematocrit values, and 
enhanced iron binding capacity, leading essentially to a clinical picture identical to 
secondary polycythemia [95]. Mechanistically, soluble biglycan induces polycythemia by 
triggering the hepatic and renal expression of erythropoietin (Epo), a key regulator of 
erythropoiesis. This occurs exclusively via TLR2 and involves biglycan-mediated 
stabilization of HIF-2α, most likely through a hypoxia-independent pathway [95].(Fig. 3). 
This information provides a new link for biglycan in the regulation of inflammation via 
stabilizing HIF-2α, a crucial trigger of pro-inflammatory cytokines, in macrophages [96]. 
Furthermore, these findings are in line with previous reports that biglycan selectively 
interacts with TLRs and their adapter molecules to achieve diverse biological outcomes 
[87,89]. While the clinical relevance of these findings has not been shown yet, it is 
conceivable that biglycan may critically impact tumorigenesis and cardiovascular disease by 
enhancing HIF-2α abundance and triggering secondary polycythemia.
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Inflammatory biglycan signaling in tumor cell biology
Despite growing evidence for a relationship among innate immunity, inflammation, and 
tumor development, the mechanisms responsible for this association are not well-defined 
[97,98]. Although inflammation is a beneficial and essential mechanism in tissue injury and 
pathogen defense, it requires a rapid clearance of inflammatory cells [99]. Imbalance of 
inflammation resolution leads to infiltration of immune cells, which may generate large 
amounts of cytokines, chemokines, and ROS resulting in tissue damage and chronic 
inflammation, thus contributing to tumor initiation and progression [100]. Furthermore, the 
inflammatory microenvironment is considered a hallmark in each stage of tumor 
development [98].
Taking into account the intimate involvement of biglycan in inflammation, it is not 
surprising that the overexpression of biglycan is associated with a variety of human 
malignancies, such as pancreatic adenocarcinoma [101,102], colon cancer [102], ovarian 
cancer [103] intrahepatic cholangiocarcinoma [104], gastric cancer [80], esophageal 
squamous cell carcinoma [105], and melanoma [106]. Moreover, biglycan is involved as a 
regulator of tumorigenesis [60], a prognostic marker for cancer progression and survival 
[107], and a target for colon cancer diagnostics and treatment [108]. It is conceivable that 
biglycan triggers tumorigenesis directly via TLR2/4-NF-κB- and P2X7-NLRP3-caspase-1-
signaling or indirectly via downstream mediators such as pro-inflammatory cytokines, NOX 
enzymes, ROS, HIF-2α, Epo and VEGF [30,77,83,85,86,89,95] (Figs. 2 and 3). Indeed, 
there is mounting evidence that activation of TLR2 and TLR4 leads to cancer progression 
due to increased tumor cell proliferation, resistance to apoptosis, increased production of 
growth factors (e.g. TGF-β, VEGF) and of pro-inflammatory cytokines [109–111]. 
Downstream of TLR2/4, the adaptor molecule MyD88 and its oncogenically-active mutant 
forms, are considered mediators of tumorigenesis in various cancers [112]. Beyond that, 
there is no doubt that constitutive activation of NF-κB and MAPK pathways cause chronic 
inflammation which would favor cancer progression. The complex regulation of 
inflammation by biglycan is a result of signaling crosstalk between TLR2/4- and P2X7-
NLRP3-caspase-1-pathways [88,113,114]. While direct data on biglycan-NLRP3-caspase-1-
signaling in carcinoma cells are not available yet, there is strong evidence for pro-
tumorigenic effects of the NLRP3-caspase-1 signaling pathway [115,116]. Enhanced 
expression and activation of NLRP3 and caspase-1 is considered a poor prognostic sign for 
oncologic patients [115]. Therefore the development of inhibitors selectively targeting the 
NLRP3 inflammasome could be of potential therapeutic value.
Besides directly triggering pro-inflammatory TLR- and inflammasome-signaling, biglycan 
stimulates the generation of pro-inflammatory cytokines, NOX enzymes, ROS, HIF-2α, Epo 
and VEGF, which are crucial mediators of inflammation and angiogenesis in cancer 
development. Accordingly, enhanced generation of NOX-derived ROS in inflammatory 
tumors causes chromosomal DNA alteration and genomic instability, as well as induces 
tumor cell proliferation, survival, and metastasis [117,118]. Furthermore, enhanced HIF-2α, 
which might be due to biglycan-TLR2-dependent HIF-2α stabilization [95], has been 
detected in a variety of tumors with diverse histogenetic background [119,120]. 
Interestingly, there is growing evidence that generation of HIF-2α in cancer is restricted to 
Schaefer et al. Page 10
FEBS J. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
tumor-associated macrophages (TAMs) [119,121]. By regulating the expression of VEGF, 
VEGF receptors 1/2 and angiopoietins in TAMs, HIF-2α induces tumor angiogenesis and 
triggers the expression of genes involved in tumor cell proliferation and tumor invasion 
[122–124]. On the other hand, biglycan has been described to trigger endothelial cell 
migration and neovascularization of tumors due to its ability to induce VEGF synthesis in a 
TLR2/4-dependent manner [32,77,111]. Additionally, biglycan can generate a reservoir for 
VEGF, which in turn can be released during tumor-associated ECM-degradation, thus 
promoting angiogenesis [125]. Moreover, soluble biglycan is expressed in highly metastatic 
tumor endothelial cells, where it promotes tumor cell migration [126]. Thus, it is 
conceivable that during cancer development enhanced biglycan levels could promote 
stabilization of TAM-derived HIF-2α (Fig. 3) and trigger VEGF production and 
sequestration. Both bioactivities would ultimately trigger tumor angiogenesis.
During tumorigenesis a cross-talk between tumor and stromal cells modifies the 
microenvironment and the ECM [127]. The expression of biglycan by stromal fibroblasts is 
induced by TGF-β, a multi-purpose growth factor [128,129] which might then use the 
TLR2/4 on stromal macrophages to further modulate the tumor microenvironment and to 
induce the recruitment of tumor cells through chemokine production. In addition, biglycan is 
able to increase the affinity of TGF-β to its receptor and therefore promote cancer 
progression. Thus, we presume, that biglycan-triggered TGF-β signaling might create an 
environment, which is prone to tumor development, by triggering the expression of matrix 
proteins and enzymes involved in matrix remodeling [130,131]. Moreover, TGF-β activates 
fibroblast-to-myofibroblast differentiation [132,133], as well as epithelial-to-mesenchymal 
transition (EMT) [134] thus increasing the potential for metastasis. Furthermore, decorin 
interacts with TGF-β [62], to inhibit its signaling pathway, resulting in the reduction of 
fibrosis [135]. Interestingly, TGF-β inhibits decorin transcription [136], a finding opposite to 
the TGF-β-mediated induction of biglycan. These disparate functions of decorin and 
biglycan in the context of TGF-β signaling solidify the contrasting effects seen on 
tumorigenesis by these related proteoglycans, where one diminishes tumor progression 
while the other promotes disease.
Enhanced Epo production based on biglycan-TLR2-HIF-2α signaling [95] provides an 
additional indirect mechanism of biglycan promoted tumorigenesis. Upon binding to 
erythropoietin receptors present on carcinoma cells, Epo promotes tumor growth, local 
invasion, metastasis, angiogenesis and lymphangiogenesis [137–140] (Fig. 3). Thus, there is 
a plethora of direct and indirect mechanisms through which biglycan promotes inflammation 
and angiogenesis resulting in tumor progression.
Besides strong indications for pro-oncogenic functions of biglycan, there are also some 
reports describing tumor suppressive effects of biglycan. For example, biglycan induces cell 
growth arrest in pancreatic cancer cell lines in vitro [78] and inhibits bladder cancer cell 
proliferation [141]. Interestingly, although elevated levels of biglycan correlate with high-
grade human bladder cancer and muscle invasiveness, enhanced expression of tumor-
associated biglycan is linked to a better survival rate [141]. Accordingly, knockdown of 
biglycan leads to increased proliferation of bladder cancer cells, indicating biglycan as an 
endogenous inhibitor of cancer cell growth in urothelial neoplasms [141]. In addition, 
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biglycan induces a high intratumoral inflammatory reaction as well as an enhanced 
autologous tumor response in diffuse large B-cell lymphomas, leading to improved 
therapeutic outcome and survival [142]. Presumably, this dual role of biglycan in 
tumorigenesis depends on the tumor cell type and differentiation stage (Fig. 2). According to 
our current knowledge, a biglycan-mediated chronic inflammatory milieu should promote 
tumor growth. However, acute inflammation caused by administration of biglycan into 
established tumors actually reduces malignant growth, analogous to beneficial effects of 
decorin-TLR2/4 signaling [143] (Fig. 2).
Taken together, the multifunctional involvement of biglycan in the regulation of 
inflammation makes it a potentially druggable target for cancer remedies as well as a novel 
anti-oncogenic therapeutic agent on its own.
Pro-inflammatory signaling of decorin
Analogous to biglycan, decorin induces a TLR2/4-dependent signaling cascade in 
macrophages leading to the activation of the MAPK, ERK, stress-activated protein kinase 
(SAPK) and p38 signaling pathways, and subsequently to the synthesis and secretion of 
CCL-2, TNF-α and IL-12p70 [143,144]. Moreover, decorin possesses the ability to further 
drive the cytokine profile toward a pro-inflammatory phenotype by impeding the production 
of the anti-inflammatory cytokine, IL-10, by macrophages. By sequestering active TGF-β, 
decorin reduces the abundance of TGF-β-driven oncogenic microRNA (miR)-21. miR-21 is 
a translational inhibitor of the tumor suppressor programmed cell death protein 4 (PDCD4), 
which itself post-translationally suppresses IL-10. Consequently, increased PDCD4 
production causes reduction of IL-10 protein abundance [143]. Indeed, due to creating an 
inflammatory milieu in the tumor microenvironment together with reduction of the 
oncogene miR-21 and enhancement of the tumor suppressor PDCD4, decorin inhibits 
growth of established tumors [143]. Thus, decorin, as an important modulator of malignant 
growth, metastasis and tumor microenvironment [67,68,145–148] might be a useful tool for 
anti-tumor interventions.
Conclusions and perspectives
The functions of decorin in tumor biology continue to surface as more sophisticated research 
tools become available [149,150]. Though decorin has been touted as a “guardian from the 
matrix” for many years, this designation was primarily given due to its ability to alter RTK-
signaling, resulting in reduction of tumor growth via cell cycle arrest. More recent work 
demonstrates the incredible versatility of this SLRP as decorin has now acquired a new role 
as a potent autophagic inducer in endothelial cells and a pro-mitophagic agent in tumor cells. 
The ability for decorin to regulate these signaling pathways offers a new perspective on 
matrix-regulation of both the tumor microenvironment as well as the tumor proper. 
Specifically, the capacity of decorin to both inhibit angiogenesis as well as act directly on 
the tumor proper makes it an ideal candidate for drug design. Furthermore, as decorin is a 
naturally-occurring proteoglycan, the side effects of using purified decorin or its biologically 
active fragments will likely be minimal, making it an attractive option for chemotherapy.
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Moving to biglycan, research of the last two years has exponentially improved our 
knowledge regarding the role of this SLRP in inflammation and angiogenesis. There is now 
evidence that, besides mediating inflammation by biglycan, TLR2/4 are required for 
biglycan-dependent synthesis of VEGF and, therefore, regulation of angiogenesis. 
Furthermore, it became clear that biglycan is not only a pro-inflammatory stimulus but is 
also capable of self-limiting inflammation. The underlying mechanism of how biglycan 
tightly balances pro- and anti-inflammatory responses under physiological conditions has 
been provided [89]. Hopefully, these data will encourage further research on the mechanisms 
regarding anti-inflammatory signaling of other ECM-derived danger signals.
Beyond the well-known biglycan-dependent orchestration of various receptor signaling, 
another level of complexity in biglycan-dependent regulation of inflammation has recently 
been described [89]. It is now obvious that besides common signaling via TLR2 and TLR4, 
biglycan selectively binds to only one TLR. After choosing the receptor, the next step of 
signaling is achieved at the level of TLR adaptor molecules, finally resulting in a very 
specific downstream outcome. This might explain why, in certain cell types and under 
certain conditions, biglycan could actually suppress tumorigenesis. The mechanisms of how 
this selection of receptors and adaptors is regulated are not known yet. It is conceivable, 
however, that various co-receptors might help biglycan to “make that specific choice”.
One example for a specific outcome of biglycan-TLR2 signaling is the newly-identified 
function of biglycan to stabilize HIF-2α and increase Epo production [95]. The exact 
mechanisms for biglycan-mediated HIF-2α stabilization still need to be elucidated. 
Although little is known about the biglycan-HIF-2α-Epo signaling axis during 
tumorigenesis, it is likely that the blockade of biglycan/TLR2-binding could protect against 
malignant growth. However, given that TLRs have crucial physiological functions, future 
studies are essential to unravel co-receptors and downstream mechanisms of biglycan/TLR-
signaling for selective druggability in the context of cancer.
In conclusion, both decorin and biglycan are important mediators of tumor initiation and 
progression involving the cellular pathways of angiogenesis, inflammation, and autophagy. 
As the tumor microenvironment is a complex amalgam of different cell types and signaling 
molecules, it is probable that these critical cellular processes are intertwined in an intricate 
system to alter cell growth, metastasis, and nutrient availability for both normal and cancer 
cells. Therefore, it is important to focus on these pathways and their regulation by these and 
other matrix constituents in order to gain a closer understanding of the timeline of events 
involved in tumor initiation as well as to define which pathways are deregulated leading to 
tumor progression. Future therapeutic modalities will materialize as the nuances of these 
signaling pathways are elucidated, and thus it is essential to continue our efforts of 
unravelling the role of these proteoglycans in normal and aberrant physiology.
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Abbreviations
AMPK adenosine monophosphate kinase
CCL chemokine (C–C motif) ligand
CS/DS chondroitin sulfate/dermatan sulfate
CXCL chemokine (C-X-C motif) ligand
ECM ECM
EGFR epidermal growth factor receptor
Epo erythropoietin
ERK extracellular signal-regulated kinases
GAG glycosaminoglycan
HGF/Met hepatocyte growth factor
HIF hypoxia inducible factor
HSP heat shock protein
HSPG2 heparan sulfate proteoglycan 2
IL interleukin
LC3 microtubule-associated protein light chain 3
LRP6 LDL-receptor related protein 6
MyD88 Myeloid differentiation primary response protein
NOX NADPH oxidase
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NLRP3 NOD-like receptor protein 3
PDGF platelet-derived growth factor
Peg3 paternally expressed gene 3
ROS reactive oxygen species
SLRP small, leucine-rich proteoglycan
TAM tumor associated macrophages
TLR Toll-like receptor
TGF-β transforming growth factor β
TRIF Toll/IL-1R domain-containing adaptor inducing IFN-β
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VEGF vascular endothelial growth factor
VEGFR2 vascular endothelial growth factor receptor 2
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Fig. 1. 
Decorin exhibits promiscuity in its ability to alter tumorigenesis via regulation of 
angiogenesis, autophagy, and inflammation. Decorin antagonizes RTKs, such as EGFR and 
Met, on the tumor cell surface to inhibit angiogenesis via suppression of pro-angiogenic 
factors, such as VEGFA, as well as induction of anti-angiogenic proteins, such as 
thrombospondin-1, while simultaneously reducing tumor growth via cell cycle arrest and 
inhibition of Myc and β-catenin. Signaling through Met also induces mitostatin leading to 
tumor cell mitophagy. Interaction between decorin and VEGFR2 in endothelial cells results 
in autophagic induction vis-à-vis the canonical intermediates, Beclin 1 and LC3 as well as 
with the novel autophagic regulator, Peg3. In inflammatory cells, decorin signals through 
TLR2/4 to induce pro-inflammatory mediators, which reduces tumor growth.
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Fig. 2. 
Dual role of biglycan in the control of inflammation and tumorigenesis. Soluble biglycan 
triggers mRNA expression of pro-inflammatory cytokines and chemokines Il1β, Cxcl1, 
Cxcl2, and Ccl2 in macrophages in a TLR2/4- and MyD88-dependent manner, while it 
selectively stimulates the expression of Ccl5 through TLR4 and TRIF. By clustering TLR2/4 
and the P2X7 soluble biglycan induces the NLRP3-inflammasome, activating caspase-1 and 
releasing mature IL-1β. Moreover, biglycan directly mediates the expression of Nox2 
mRNA via TLR4/TRIF and the activation of NOX2 in a TLR4/MyD88-dependent manner, 
thereby attenuating the expression of the pro-inflammatory cytokine IL-1β. In contrast, by 
engaging TLR2, soluble biglycan triggers the expression of HSP70, which binds to NOX2, 
and consequently impairs the inhibitory function of NOX2 on biglycan-mediated IL-1β 
expression and maturation.
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Fig. 3. 
Biglycan induces tumorigenesis via HIF-2α stabilization and Epo expression. Soluble 
biglycan binds to the TLR2 in the kidney and/or in the liver and induces the stabilization of 
HIF-2α produced in liver, kidneys and tumor-associated macrophages (purple). HIF-2α 
subsequently induces the expression of erythropoietin (Epo). Epo is than released into the 
circulation, where it may stimulate tumor angiogenesis, cell growth and cell migration, as 
well as tumor lymphangiogenesis, thus inducing tumorigenesis.
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